Abstract
<b>Introduction:</b> To identify responders to biologic treatment, patients’ pre-therapy characteristics must be understood. <b>Aim:</b> To describe the characteristics of biologic users at initiation. <b>Methods:</b> Patients from the International Severe Asthma Registry (ISAR) who initiated a biologic therapy (anti-lgE or anti-IL5/5R) were included in this study. Characteristics of the two biologic groups were compared at biologic initiation. <b>Results:</b> Among 9211 patients from 19 countries who enrolled into ISAR from May 2015 to October 2020, a total of 1609 (17.5%%) biologic patients were included in this study. Out of which, 794 (49.3%) and 809 (50.7%) reported initiating anti-IgE and anti-IL5/5R, respectively. The table shows anti-IL5/5R patients were more likely to be older, male, older at asthma onset, receiving long-term oral corticosteroid (LTOCS), have lower BMI, and less likely to be smokers. Anti-IL5/5R patients, at the exception of emergency visits, had evidence of worse asthma control. <b>Conclusions:</b> Anti-IL5 patients had more severe asthma characteristics at initiation. Responses at post-biologic periods will inform the effect of therapy on these patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
